Meeting
2021 ASCO Annual Meeting
A phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer.
Presenter
Peter Joseph DeMaria, MD
Genitourinary Malignancy Branch, NCI, NIH
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Vaccines
Clinical Trial Registration Number
NCT04134312
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2617)
DOI
10.1200/JCO.2021.39.15_suppl.2617
Abstract #
2617
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
A phase 1, multicenter, open-label, first-in-human study of DS-6157a in patients (pts) with advanced gastrointestinal stromal tumor (GIST).
Speaker: Suzanne George, MD
Videos & Slides
2022 ASCO Annual Meeting
An open-label, non-randomized, multi-center phase I study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumors.
Speaker: Kaiwen Li
Videos & Slides
2022 ASCO Annual Meeting
First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with select advanced solid tumors.
Speaker: R. Donald Harvey, BCOP, PharmD, FCCP
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
Relugolix in combination with abiraterone acetate, apalutamide, or docetaxel in men with advanced prostate cancer (aPC): A phase 1, three-part, open-label, parallel-cohort study.
Speaker: Jose De La Cerda, MD, MPH